Friday, 7 August 2026
AHPRA privacy breach apology, Updoc telehealth data breach, Limited IBD therapy access in Australia
- 01
AHPRA apologises for privacy breach involving healthcare workers
AHPRA apologised after it inadvertently shared the private email addresses of healthcare professionals invited to a webinar on addiction and recovery. The breach occurred despite assurances of anonymity in the invitation sent on 29 July. AHPRA took immediate steps to address the issue, including notifying affected individuals and providing information on how to lodge complaints. The incident has raised concerns among invitees, some of whom expressed confusion and frustration over the breach.
via RACGP newsGP
- 02
Updoc telehealth company reports data breach affecting patient details
Telehealth operator Updoc has reported a data breach involving the potential leak of patients' email and address details due to unauthorised access to a third-party system. The company informed customers that the breach was isolated and did not involve health, financial, or payment information. Updoc took immediate action to block the unauthorised access and stated that there has been no evidence of further access since the incident. The breach raises concerns about patient privacy and data security in the telehealth sector, as highlighted by Dr Rob Hosking from the RACGP.
via RACGP newsGP
- 03
IBD Patients Face Limited Access to Effective Therapies in Australia
Patients with Crohn's disease and ulcerative colitis in Australia are increasingly missing out on effective therapies as pharmaceutical companies opt not to launch innovative treatments locally. The Bitter Pill report reveals that only 25% of innovative medicines launched globally in the past decade have been reimbursed through the Pharmaceutical Benefits Scheme (PBS), significantly lower than in the UK and US. This situation leaves approximately 180,000 Australians with inflammatory bowel disease facing avoidable surgeries and complications due to a lack of treatment options. Gastroenterologist Associate Professor Réme Mountifield emphasises that access to a range of therapies is crucial for managing IBD effectively, as no single medication works for every patient.
- 04
AMA opposes expanded regulations on financial consent
The AMA has rejected proposals from the Department of Health, Disability and Ageing to tighten informed financial consent regulations, arguing that current scrutiny of doctors' fees is causing distress among clinicians. The Department's consideration includes expanding the remit of various regulatory bodies to handle financial consent complaints, which the AMA cautioned could lead to more complex regulatory environments and discourage practitioners. The AMA advocates for patient and provider education as a more effective approach, highlighting the challenges in accurately estimating treatment costs and the potential for vexatious complaints. It emphasised the need for any government intervention to be proportional and based on peer review.
- 05
New strategy aims to enhance primary care nurses' roles
The National Nursing Workforce Strategy will enable nurses to work to their optimum scope of practice in rural settings, according to Health Minister Mark Butler. The strategy, launched at the Australian College of Nursing conference, outlines 28 priorities to strengthen the nursing workforce, focusing on enabling innovation and enhancing sustainability. Butler emphasised that increasing nurses' scope of practice will improve patient care and retention of nursing staff. The Australian Primary Care Nurses Association welcomed the strategy, noting that allowing nurses to work fully can reduce burnout and improve career satisfaction.
- 06
Gefurulimab shows promise in myasthenia gravis trial
An international phase III study demonstrated the safety and efficacy of gefurulimab, a once-weekly self-administered treatment for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis. The trial met all primary and secondary endpoints, showing clinically meaningful improvements as early as the first assessment after treatment initiation and sustained effects through week 26. Two hundred and sixty adults participated, with gefurulimab showing greater reductions in Myasthenia Gravis scores compared to placebo. Adverse events occurred at similar rates in both groups, with no deaths linked to the treatment. Researchers noted gefurulimab's design offers advantages over existing therapies, potentially providing patients with more autonomy.
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.